Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07534371) titled 'Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study' on April 8.
Study Type: Observational
Primary Sponsor: West China Hospital
Condition:
Neuroendocrine Tumors
Intervention:
Drug: surufatinib
Recruitment Status: Not recruiting
Date of First Enrollment: March 6, 2026
Target Sample Size: 500
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07534371
Disclaimer: Curated by HT Syndication....